Tyra Biosciences, Inc. announced that it has entered into a securities purchase agreement with institutional and accredited investors to sell securities 9,286,023 shares (the Shares) of the Company?s common stock, par value $0.0001 per share, at a price of $13.01 per Share for a gross proceeds $120,811,159.23, and with respect to certain Purchasers, pre-funded warrants to purchase an aggregate of 6,087,230 shares of Common Stock (the Pre-Funded Warrants) in lieu of shares of Common Stock, at a purchase price of $13.009 per Pre-Funded Warrant for gross proceeds of $ 79,194,862, to the aggregate gross proceeds of $200,006,021.23 on February 1, 2024. The transaction will include participation from new investors such as OrbiMed Advisors LLC, 5AM Venture Management, LLC and returning investors such as RA Capital Management, L.P., Boxer Capital LLC, BVF Partners L.P. and Nextech Invest Ltd. The transaction is expected to close on February 6, 2024, subject to customary closing conditions. The securities described above have not been registered under the Securities Act of 1933, as amended.